Requesting nullity of a patent in France: beware of time limitations


However on March 16, 2017, the judges decided that Actelion Pharmaceuticals’ request for invalidating European patent No. 1 200 092 owned by ICOS Corporation had not been timely lodged.

The Court referred to the statutory period of limitation which restricts civil actions to “five years following the day on which the owner of a right has known or should have known the facts allowing to exercise it” (as amended in 2008, by Article 2224 of French Civil Code). In consistency with earlier decisions, the Court considered that Actelion Pharmaceuticals was such “owner of the right” [to bring an invalidity action]. Interpreting what the “facts allowing to exercise” this right were, was more difficult. In a bizarre reasoning, the Court held that the starting point for this limitation period was the date on which the patent owner (namely ICOS Corporation) was granted a marketing authorization for its drug Adcirca® (tadalafil) to which the patent was considered to relate (although it does not protect tadalafil per se) . The Court indeed assumed that, at the date of this marketing authorization, “the Plaintiffs [Actelion] had known or should have known that patent EP 092 was such that it could represent a bar to their economical activity and that it could be opposed by its owner.”

Patent professionals advocate for adding specific provisions into the French patent Code in order to clarify the limitation, if any, and overcome this uncertainty.

In the meantime, generic companies and alleged infringers should not despair: they can still request inter partes invalidity as a counter claim in an infringement action.

Emmanuelle RENARD

Find our lastest news

European Patent Office (EPO) - Office Européen des Brevets (OEB)

G2/21: A landmark decision of the Enlarged Board of Appeal on “Plausibility”

To be or not to be plausible, that is no longer the question. On March 23, 2023, the Enlarged Board of Appeal of the European patent office (EPO) rendered its long awaited decision addressing the question as to whether relying on post-filing evidence should be accepted to support inventiveness of a claimed invention. Many examination […]

3 April 2023

Learn more

Leaders League rankings 2023

We are proud to inform you that Becker & Associés has been distinguished once again by Leaders League as one of the top leading French patent firms in the Chemistry-Biotech-Life Science areas.

28 March 2023

Learn more

The Unitary patent: revised calendar

For technical reasons, the Unified Patent Court (UPC) has decided to postpone the start of the “sunrise period” to March 1, 2023. During this period, owners of European patents and patent applications may opt out from the exclusive jurisdiction of the JUB (“opt-out”), before the agreement on the unified patent jurisdiction enters into force in June 1, […]

8 December 2022

Learn more


The Unitary Patent (UP) and the Unified Patent Court (UPC) should come into force soon. The exact date is not certain, but should be end 2022 or early 2023. The Unitary Patent (UP) is a unique IP title which will allow for a protection in several member states of the European Union, with common validation and maintenance […]

26 April 2022

Learn more


September 4, 2021

Béatrice Tézier Herman has passed away so quickly, our pain is immense. A long-standing partner of the firm, Beatrice’s commitment and wisdom had been at the heart of the development and unity of our team. Your messages tell us about how an excellent professional she was, but also about her smile, her elegance, her serenity.

13 September 2021

Learn more

A look back at 2020: Two major decisions in the European landscape of pharma patents

Year 2020 was an active year for the Court of Justice of the European Union (CJEU), the judiciary arm of the European Union (EU) that is supposed to avoid inconsistent interpretations of the EU law over the Member States. With two decisions rendered in April and July 2020, the CJEU made some progress in clarifying […]

8 January 2021

Learn more

Discover all our news
Atomes 10


    If you would like more information, please do not hesitate to contact us. Please fill in the online form.


    Cabinet Becker et Associés

    25 rue Louis Le Grand

    75002 Paris

    Métro : Opéra

    Parking : Opéra-Meyerbeer

    +33 (0)1 53 43 85 00


    Cabinet Becker et Associés

    32 cours Mirabeau

    13100 Aix-en-Provence

    Parking : Mignet

    Social media & sharing icons powered by UltimatelySocial